TransMedics Group, Inc. — Director's Dealing 2022

Dec 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-12-13

Reporting Person: Provost Miriam (VP, Global Regulatory Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-13	Common Stock	M	5918	$38.46	Acquired	19469	Direct
2022-12-13	Common Stock	S	2695	$62.24	Disposed	16774	Direct
2022-12-13	Common Stock	S	1620	$63.00	Disposed	15154	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-13	Stock Option (Right to Buy)	$38.46	M	5918	Disposed	2031-02-24	Common Stock (5918)	Direct

Footnotes

F1: The exercise followed the sell-to-cover process, whereby a portion of the shares acquired through the exercise were sold in the open market, with the proceeds used to fund the aggregate exercise price of the options.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $61.70 to $62.69, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.72 to $63.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.